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 ABSTRACT 
The budding yeast Saccharomyces cerevisiae shows substantial polarity 
during its growth. Membranes and proteins are constantly transported to 
the growth sites, almost exclusively mediated by the Myosin motor Myo2p. 
Myo2p recognizes its cargos by interacting with different cargo-specific 
adaptors and its function also relies on other accessory proteins. Among 
them, the kinesin-like protein Smy1p was interesting due to its genetic 
interactions with sec2, sec4 and myo2 mutants. However, current models 
have problems reconciling all the previous findings. Whether Smy1p has a 
function in polarized secretion and how Smy1p exerts its function are 
largely unknown. To address these questions, different approaches were 
employed in this research. First, Smy1p localization was determined and I 
found it to rely on interactions with Myo2p. Further truncation analysis 
revealed a complicated localization and expression level regulation. Second, 
Smy1p protein depletion in myo2 conditional mutants was found to cause a 
massive secretion block and this method can be applied to other mutants 
like sec2-56, sec4-8 as well. Third, I identified over 30 smy1 mutants in 
different myo2 sensitized strains, studying of which will greatly increase our 
understanding of the mechanism underlying Smy1p’s function. 
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CHAPTER 1: INTRODUCTION 
1.1 Cell Polarity 
Polarity is a common feature of most eukaryotic cells. For example, 
mammalian epithelial cells (Fig 1.1A) have two domains, a basolateral 
domain and an apical domain. Each domain has different structures and 
different protein/lipid components. This specific organization allows the 
cell to carry out its normal function and therefore is essential for cell 
growth.  
To study cell polarity, we use the budding yeast Saccharomyces 
cerevisiae as a model (Fig 1.1B). Budding yeast has a very simple life 
cycle. At the beginning of each cell cycle, the mother cell chooses a 
budding site to form a small bud. As the cell cycle proceeds, the bud 
grows until it reaches certain size, when new cell wall forms between the 
mother and the daughter cell and separates them, thereby finishing the 
cell cycle (Sherman, 2002). How budding yeast adopts this highly 
asymmetric cell shape and achieves such a polarized growth with 
exceptional accuracy is always intriguing for cell biologists. The basic 
mechanism underlying this process may very well be conserved and be 
applied to research in higher organisms. 
In the following sections I will briefly describe what we know about the 
principles of yeast polarity establishment and what problems we are 
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investigating in our lab, especially in my project. 
 
Figure1.1 Polarity is a common feature of eukaryotic cells  
(A) mammalian epithelial cells have two domains: apical and basolateral domain 
(B) Saccharomyces cerevisiae has a bud and a mother cell 
Microtubules are shown in green, actin filaments are shown in red. 
These schematics are adopted from Felipe Santiago-Tirado’s work.  
1.2 Polarized Secretion 
Polarity establishment requires orderly and timely delivery of protein, 
lipids and other components. In yeast, multiple membrane 
compartments, including Golgi, vacuole (Weisman et al., 1990), 
mitochondria, peroxisome and secretory vesicles, are transported from 
the mother to the bud during bud emergence, because inheritance of 
these organelles is very important for the normal function of the 
newly-formed daughter cell. However, except for mitochondria, most of 
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these organelles can be generated de novo, while the secretion of lipids 
and protein from ER, Golgi to the plasma membrane (so-called polarized 
secretion) is essential for bud growth. Therefore, we will focus on that in 
this thesis. 
Continuous delivery of secretory vesicles enables the bud to grow simply 
in two aspects. First, newly synthesized protein and lipids are added as 
the secretory membranes fuse with the plasma membrane, providing 
the substance for the expansion of the surface area. Second, enzymes 
and other material are secreted outside the cell, remodeling the cell wall 
and allowing the growth to occur. So how does the cell know what to 
secrete? 
It took almost 40 years to understand the principle dominating this 
complicated process. First of all, secretory proteins exhibit an N-terminal 
signal peptide when translated in the cytoplasm, where this peptide is 
recognized by SRP complexes. SRP complexes then bind to this peptide 
and stall the translation, until captured by the SRP receptor located on 
the ER membrane. There, as the translocon is assembled, translation of 
secretory protein is resumed and the resulting peptide is translated and 
then folded and modified in ER lumen (membrane proteins work slightly 
differently). Second, these newly synthesized proteins are enclosed in 
membrane and coated by the COPII complex, which then buds from the 
ER and is transported to the Golgi complex. Note that in budding yeast, 
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since cortical and perinuclear ER are scattered, there is no obvious ER 
exit site like higher organisms. Also, the ER-Golgi intermediate complex 
(Hauri and Schweizer, 1992) cannot be clearly discriminated from early 
cisterna because the Golgi complex is scattered as well. As a result, 
transport between the ER and the Golgi actually happens through 
diffusion in yeast, while in mammalian cells active transport is involved. 
After secretory proteins reach the Golgi complex, they are subject to 
additional modifications as the cisternae matures into late Golgi and the 
Trans-Golgi Network (TGN), where sorting occurs (Losev et al., 2006). 
However, it is still unclear how vesicles are packaged at the TGN, except 
for the exomer (Wang et al., 2006) that specifically coats certain vesicles 
carrying cargos like Chs3p (a chitin synthase). At last, TGN gradually 
mature and break into secretory vesicles, containing all the protein and 
lipids needed for the new bud, and are transported to the growth site. 
There, with the help of the tethering complex exocyst (Guo et al., 1999), 
which consists of 8 different proteins (Sec3p, Sec5p, Sec6p, Sec8p, 
Sec10p, Sec15p, Exo70p, and Exo84p), these vesicles are docked at the 
plasma membrane, and subsequently fuse, driven by SNARE proteins.  
As you can see, polarized secretion involves active transport of cargoes 
into the bud. Then how could this directional transport be possible?  
1.3 Actin Cytoskeleton 
The key to polarized transport is to organize a polarized cytoskeleton. In 
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budding yeast, the actin cytoskeleton is the dominant transportation 
track (Adams and Pringle, 1984), in contrast to higher organisms where 
microtubules and actin are both important. The actin cytoskeleton in 
yeast is further divided into three forms: actin patches, actin cables and 
the cytokinetic ring (Kilmartin and Adams, 1984). Actin patches are 
involved in endocytosis (Kaksonen et al., 2003) and therefore is beyond 
the scope of this study. I will talk more about actin cables below. 
Actin monomers can easily self-polymerize into filamentous structure in 
vitro. However, in vivo actin monomers are bound to profilin, which 
prevents self-assembly and directs assembly by regulated processes 
(Haarer et al., 1990). The regulators that cooperate with profilin to form 
actin cables are formin proteins (Imamura et al., 1997), actin nucleators 
that contain catalytic FH1 and FH2 domains (Pruyne et al., 2002). In yeast 
there are two of them, Bni1p and Bnr1p, which are partially redundant. 
Bni1p localizes to the bud tip, while Bnr1p localizes to the bud neck. 
Once recruited to the right place, they are activated and start nucleating 
actin assembly by interacting with profilin-bound actin monomers. 
Formin activity is tightly regulated, since mislocalized formin activity has 
adverse effect on cell growth (Liu et al., 2012). At the same time, the 
actin filaments formed are always of roughly the same length 
(0.3-0.5μm), but bundled by fimbrin (Adams et al., 1991) and stabilized 
by tropomyosin (Liu and Bretscher, 1989) to form the long actin cables. 
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As formins stay at the barbed end of the actin filaments and are 
anchored on the plasma membrane, the cell is able to have a polarized 
actin cytoskeleton (Fig 1.3), which provides the track for active transport. 
 
Figure 1.3 Actin cable Assembly in budding yeast. This is adopted from a 
review (Pruyne et al., 2004). Formins are actin nucleators. Bni1p localizes to the 
bud tip while Bnr1p localizes to the bud neck. Actin filaments nucleated from 
them are decorated by fimbrin and tropomyosin to form the long actin cables. 
1.4 MyosinV Myo2p 
Polarized transport is not possible without the motor proteins that travel 
along actin cables. In budding yeast, the myosin-V family motor Myo2p is 
the main motor that carries out most of the transport, including 
secretory membranes, different organelles and astral microtubule (Yin et 
al., 2000). Therefore, a lot of our current understanding of yeast polarity 
comes from study of this protein. 
 As a myosin-V family motor, Myo2p can be divided into four different 
domains: the head domain, 
coiled-coil region and the globular tail 
Figure 1.4 (A) Myo2p is a Myosin V family motor 
graduate student Kirk Donovan. It shows different domains of Myo2p
 
The head domain, also called the motor domain, is conserved through 
the myosin-V family, which binds actin cables and has ATPase activity. 
Myosin-Vs have a high duty
motor domain remains bound to actin
Therefore, most of them are processive motors, walking along actin 
cable for several steps before falling off. However, Myo2p was considered 
an unusual myosin-V because 
non-processive (Hodges et al., 2009)
motor in vivo, as the motor itself could reach the bud tip when detached 
from its secretory cargo
their tail domain (Schott et al., 199
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the neck domain containing 
domain (GTD) (Fig 1.4A
This diagram was made by 
-cycle, which means over 90% of the time the 
 (De La Cruz et al., 1999)
in previous in vitro experiments 
. Despite that, Myo2p is a processive 
 in myo2 conditional mutants with mutations on 
9).  
IQ motifs, a 
).  
 
. 
. 
it was 
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The neck domain with IQ motifs is responsible for light chain and 
calmodulin binding (Espindola et al., 1992), and recently found to be also 
the binding site of Sro7p (Rossi and Brennwald, 2011). Myo2p has 6 IQ 
motifs, with different preference to different binding partners. However, 
this domain is not essential, as a 0-IQ mutant generated in our lab is still 
partially functional (Schott et al., 2002). From the same work, we also 
found that the number of IQ motifs determines the transport rate of the 
motor, which normally involves steps of 36 nm for 6 IQ motifs. Therefore, 
the IQ motifs are called the lever arm. 
The coiled-coil region mainly dimerizes this molecule, but is also 
implicated in binding to Rab proteins (Roland et al., 2011; 
Santiago-Tirado et al., 2011). Mammalian Myosin-V has three coiled-coil 
regions, while Myo2p only has one. That’s why some conserved residues 
in mammalian myosin-Vs cannot be found in yeast. 
The globular tail domain (GTD) of Myo2p is vital for its function, since it 
is the cargo-binding domain (Schott et al., 1999). With its structure 
solved (Pashkova et al., 2006), and different point mutations available, 
the field has a fairly good understanding of its organization and function 
(Fig 1.4B). The GTD can be divided into sub-domain 1 and sub-domain 2. 
Sub-domain 1 is mainly responsible for binding to vacuole and 
mitochondria, while sub-domain 2 mainly binds secretory compartments 
(Pashkova et al., 2005). Some of the important surface residues that 
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affect Rab binding have been revealed (Eves et al., 2012), which will be 
covered in the following chapters.  
How could Myo2p recognize so many different cargos with only one tail 
domain? The answer lies in adaptor proteins.  
 
Figure 1.4 (B) Myo2p tail structure and adaptor binding site. This is adopted 
from a most recent paper (Eves et al., 2012). Different binding sites for different 
adaptors are shown. The Rab binding site is mainly around helix 9, which 
overlaps with Inp2 and Kar9 binding site. 
1.5 Adaptors 
The idea that the myosin motor binds its cargo through an intermediate 
adaptor protein has been proposed for many years. For example, vacuole 
adaptors are Vac8p-Vac17p (Ishikawa et al., 2003) and mitochondria uses 
Mmr1p and Ypt11p (Itoh et al., 2004). In mammalian cells, melanosomes 
need Rab27a to be transported by myosin Va (Strom et al., 2002). Rab 
proteins, a family of small GTPase that can switch between GDP and GTP 
bound state, are perfect candidates for regulating complicated 
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membrane trafficking, by binding to motors proteins. Indeed, in yeast, it 
was found that different organelles employ different adaptors, of which 
Rab proteins are commonly used. We are more interested in the 
post-Golgi secretion process, where a Rab cascade (Mizuno-Yamasaki et 
al., 2010) is involved (Fig 1.5). 
 
 
Figure 1.5 Rab cascade happens in late secretion. This is adopted from Novick 
group’s paper (Mizuno-Yamasaki et al., 2010). Sec2p is in blue, Ypt32p is in 
yellow, Sec4p is in red and Sec15p is in green. As PI4P level drops, Sec15p 
gradually displaces Ypt32p. 
 
Rab proteins Ypt31p/Ypt32p are localized on late Golgi cisternae and the 
TGN, where they serve as the Myo2p receptor. At the same time, the 
Novick lab found that, by binding to PI4P and Ypt31p/Ypt32p, Rab GEF 
Sec2p also localizes to these compartments. Sec2p may also contribute 
to Myo2p binding, although the significance of this interaction has not 
been confirmed (unpublished work from Felipe Santiago-Tirado). As 
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these membrane compartments are moved towards the bud, they 
gradually mature and the Rab GTPase Sec4p is recruited and activated by 
Sec2p. Sec4p has been long proposed to be the Myo2p receptor on 
secretory vesicle. However, it was not confirmed until Felipe 
Santiago-Tirado in our lab used a series of myo2 tail mutants that lack 
the interaction with Sec4p and characterized their phenotype 
(Santiago-Tirado et al., 2011). What’s more, Felipe also found that 
increasing PI4P level on secretory compartments could partially suppress 
some myo2 tail mutants, suggesting a coincidence detection model 
where PI4P serves as part of the receptor. The only mystery left is how 
Myo2p binds to PI4P when no direct interaction could be found. One 
hypothesis favored by our lab is that an intermediate factor physically 
links Myo2p and PI4P, though such a protein has not yet been identified. 
Once activated, Sec4p binds to its effecter Sec15p (Ortiz et al., 2002), 
which in turn displaces Ypt31p/Ypt32p (Mizuno-Yamasaki et al., 2010). 
Sec15p is part of the exocyst complex and it also binds to Myo2p. This 
interaction was recently found to affect Myo2p binding and secretion, 
although very weakly (Jin et al., 2011).  
With all these findings, it seems that how Myo2p transports secretory 
compartments is quite clear. However, there are still some mysteries to 
be solved, of which Smy1p is one. 
1.6 Smy1p 
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Kinesin-like protein Smy1p was identified in 1992 by the Lillie and Brown 
group in a multi-copy suppressor screen for the Myo2p head mutant 
myo2-66, which is the first myo2 mutant (Lillie and Brown, 1992). Later it 
was discovered to also suppress most conditional myo2 tail mutants 
generated by a former graduate student Daniel Schott in our lab. smy1Δ 
cells show a very modest phenotype, but smy1Δ is synthetic lethal with 
sec2-56, sec4-8 and myo2 tail conditional mutants (except for myo2-14), 
indicating its involvement in polarized secretion. The authors tried to 
correlate Smy1p function to its kinesin activity, proposing that Smy1p 
travels down the microtubule to polarized growth site and brings Myo2p 
to the right destination. Indeed, Smy1p interacts with Myo2GTD through 
its tail domain (Beningo et al., 2000). Smy1p overexpression causes 
Myo2p to be hyperpolarized in WT cells and restores Myo2p polarization 
in the myo2 mutants (Beningo et al., 2000). However, using the 
microtubule destabilizing drug nocodazole, the same group found that 
Smy1p function doesn’t need microtubules but relies on functional actin 
cytoskeleton instead (Lillie and Brown, 1998). Later it became clear that 
Smy1p is a passenger on secretory vesicles moved by Myo2p 
(Chesarone-Cataldo et al., 2011). How does Smy1p exert its function? 
Two recent models were proposed.  
In the first one, the authors used quantum dots to mimic secretory 
vesicles and in vitro assays to show that Myo2p cannot undertake 
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continuously long-range movement along actin bundles without Smy1p. 
In addition, they showed that Smy1p can randomly diffuse along actin 
bundles, indicating a weak interaction between them. Lastly, they 
claimed that Smy1p co-localizes with Sec4p, a vesicle marker. As a result, 
Smy1p was proposed to bind to secretory vesicles as well as Myo2p, and 
functions as an electrostatic tether to actin cable that enhances the 
processivity of Myo2p (Hodges et al., 2009) (Fig 1.6A). However, this 
model is questionable because we know Myo2p should be a processive 
motor in vivo (Schott et al., 1999) and a recent paper from the same 
group proposed that adding tropomyosin to the system would make 
Myo2p processive (Hodges et al., 2012). Besides, it is inconsistent with 
our finding that Smy1p overexpression also suppresses myo2 tail 
conditional mutants, which are detached from secretory vesicles at the 
restrictive temperature.  
 
Figure 1.6 (A) Smy1p works as electro static tether and helps Myo2p walk on 
actin bundle. This is adopted from Trybus group’s paper (Hodges et al., 2009). 
The green motor is Smy1p, red ball is Qdot, and blue motor is Myo2p. 
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The second group suggested Smy1p is a formin regulator that specifically 
suppresses the activity of Bnr1p, so that disrupting Smy1p function 
causes abnormal actin cytoskeleton organization (Chesarone-Cataldo et 
al., 2011) (Fig 1.6B). The authors first used an in vitro actin assembly 
assay to demonstrate that when a Smy1p fragment is added, the actin 
nucleating activity of Bnr1p is largely suppressed. Then, they showed 
that smy1Δ cells have defects in actin structure. That is, actin cables 
overgrow and kink, which is not seen when BNR1 is deleted. To further 
suggest an interaction between Smy1p and Bnr1p, imaging experiments 
revealed that Smy1p marked vesicles frequently pause at the bud neck. 
However, this hypothesis is weak in three aspects. First, they only 
showed that truncated but not full-length Smy1p has a strong effect on 
the actin assembly activity of Bnr1p. Second, they failed to discriminate 
Smy1p marked vesicles from other vesicles, in order to rule out the 
possibility that pausing at the bud neck is a common behavior of all 
vesicles due to the limited space. Lastly and most importantly, this model 
is difficult to reconcile with the previous data, i.e. how Smy1p 
overexpression could suppress myo2 mutants.  
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Figure 1.6 (B) Smy1 was proposed to be a Bnr1p damper. Adopted form 
Melissa Chesarone-Cataldo et al. 2011, this figure shows that Smy1p is a vesicle 
passenger and travels to the bud neck, where it functions as a formin regulator. 
 
 
In summary, despite all the genetic interactions and phenotypes 
identified in the last two decades, Smy1p function remains a mystery. So 
I set out to explore this mystery when I joined the Bretscher lab, and in 
the following chapters I will present the data I collected, which hopefully 
could deepen our understanding of this protein. 
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CHAPTER 2: STUDY OF SMY1P LOCALIZATION 
Introduction 
Smy1p is interesting because it is a kinesin-like protein. Like most 
kinesins, it has three different domains: a head/motor domain, a 
coiled-coil region and a tail domain, presumably functioning as a dimer. 
Kinesins are microtubule-based anterograde motors, that is, they move 
towards the plus end of a microtubule in the cell (traditionally it is 
believed so, but people have found kinesins moving in the opposite 
direction). As expected, Smy1p was shown by immunofluorescence to be 
polarized at the bud tip and bud neck (Lillie and Brown, 1994). 
Surprisingly, this localization is dependent on the actin cytoskeleton but 
not microtubules. Therefore, how a kinesin-like protein could travel 
along actin cables was an interesting question for the early investigators. 
An important hint comes from the observation that Smy1p 
overexpression restores Myo2p localization in myo2-66 cells at the 
restrictive temperature, and hyperpolarizes Myo2p in WT cells. So it is 
tempting to think that there is some sort of interaction between them. 
Indeed, an interaction between Smy1p and Myo2p GTD was found 
through yeast two-hybrid (Beningo et al., 2000). And the Myo2p 
interacting domain of Smy1p was mapped to the C-terminal region or 
the tail domain. As a result, one would naturally assume that Smy1p 
binds to Myo2p and moves to the polarized growth sites together, 
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although there is no direct evidence to support this idea. 
This was unquestioned until the Trybus group proposed Smy1p is 
actually attached to secretory vesicles and acts as an electro-static tether 
to actin cables. Their evidence is as follows: First, no physical interaction 
between Myo2p and Smy1p can be detected by immuno-precipitation, 
even using purified proteins. Second, Smy1p not only travels together 
with Myo2p, but also co-localizes with Sec4p, a vesicle marker. So it 
would be reasonable to suggest that Smy1p may be just a passenger 
protein on secretory vesicles. 
This paper raised my interest to ask how exactly Smy1p achieves its 
localization. To answer this question, I used fluorescence microscopy to 
study GFP-tagged Smy1p localization in different mutants. 
Material and Method 
Vectors and Cloning 
Standard molecular cloning techniques were employed, which can be 
found in “Molecular Cloning: A Laboratory Manual, Third Edition, CSHL 
Press, 2001”. Restrictive enzymes and DNA polymerase were used 
according to the instructions in either NEB or Roche’s user manual.  
Plasmids were all from the lab database or slightly modified. The vectors 
used include pRS415, pHL-3GFP, pRS416-3mCherry, pRS306 myo2-3GFP, 
pGADT7 myo2-cctail, pAS2-smy1, pBridge-sec4ΔC, pBridge- 
sec4ΔC+NLS-smy1 and Longtine plasmid (3HA). 
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Yeast strains and transformation 
Yeast strains used are WT (BY), myo2-12(BY), myo2-14(BY), myo2-16(BY), 
myo2-24(BY), sec2-56(Novick lab), sec4-8(Novick lab) and Y strains for 
Y2H (Haiyuan Yu lab). Yeast transformation was done either using the ez- 
Frozen-EZ Yeast Transformation Kit (ZYMO Research) or following the 
LiAc protocol as described (Gietz and Woods, 2002).  
Fluorescence microscopy 
Strains were grown in 5ml of standard YPD or SD medium until OD600 
=0.8 to 1.2, spun down, washed once with same volume of ddH2O and 
resuspended in 0.5ml SD-Trp medium. After that, an agarose pad was 
made, by spotting ~200ul pre-warmed 1% agarose containing SD-Trp 
medium onto each well of a 10-well glass slip, and covered by a coverslip. 
5 mins later, the coverslip was removed, and one can spot 3.5ul of 
sample onto each well. Then, another coverslip was put atop to seal the 
agarose pad, and the cells would be ready for imaging. 
To visualize the cells, a fluorescence confocal microscope (3i system) was 
used, following the standard operating manual.  
Yeast two-hybrid 
In this experiment, Y8830 strain was transformed with the AD-myo2 
cctail plasmid, while the Y8910 strain was transformed with BD-sec4 or 
BD-smy1 plasmid. After that, strains were mated on YPD plates for 5h at 
30 to combine the two parts. The resulting diploids were grown to 
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mid-log phase and normalized to OD600=0.5. A serial dilution assay was 
performed (5X dilution), and spotted onto SD–Leu-Trp (2DO), 
SD-Leu-Trp-His (3DO) and SD-Leu-Trp-His-Ade (4DO) plates, incubated at 
either 26 or 35. 
Fractionation assay 
Basically, cells were grown in 5ml of YPD medium at 26 overnight, and 
expanded to 25ml the next day to mid-log phase. OD600 was measured 
and 25 OD unit (OD*ml) of cells were taken, spun down, washed once 
with 25ml chilled killing buffer (50mM Tris pH7.5, 1mM EDTA, 1mM 
MgCl2, 100mM sorbitol, 10mM NaN3). A second wash was performed 
with 5ml spheroplasting buffer (20mM Tris pH7.5, 1.2M sorbitol, 25mM 
βME). The cells were resuspended in 1ml digesting buffer (spherolasting 
buffer + 125ul 1mg/ml zymolyase), incubate 30 min at 37. After that, 
the cells were spun down at 1,000xg for 5min using a clinical centrifuge 
and the supernatant was discarded. The pellet was resuspended in 1ml 
lysis buffer (50mM Tris pH7.5, 1mM EDTA, 1mM MgCl2, 100mM sorbitol) 
with protease inhibitor and transferred to a 5ml homogenizer. Tubes 
were washed twice with 1ml lysis buffer, so there would be 3ml in total. 
The cells were homogenized 10~15 times on ice, with 120ul taken as 
“Input”. The rest was put in 3 equal aliquots and spun down at 600xg for 
5min in a clinical centrifuge at 4. The supernatant was the “S6” 
fraction and the pellet was the “P6” fraction. Two tubes of the “S6” 
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fraction were spun again at 13,000 for 5min. The supernatant was the 
“S13” fraction and the pellet was the “P13” fraction. One “S13” fraction 
was put into ultracentrifuge tube, spun at 100,000xg for 1h at 4. Here 
we got the “P100” and the “S100” fractions. As a control, I divided “S100” 
into two aliquots, and added 1% triton X-100 to one of them, which 
would elute off membrane bound proteins. After that, the same volume 
of lysis buffer as the “S” fraction was added into the “P” fraction to 
resuspend the pellet. At last, 200ul of sample and 50ul 5x SDS loading 
buffer were mixed, vortexed and boiled for 5min. I ran a SDS-PAGE for 
each fraction, followed by western blots using anti-HA, anti-Sec4p and 
anti-Myo2 tail antibody. 
Results 
2.1 Smy1p is a passenger protein on secretory vesicle 
Smy1p is known to polarize to the bud tip and bud neck, but we need an 
accurate way to visualize how it is transported to these growth sites. 
Therefore, live imaging using a fluorescence microscope was employed. 
WT cells were transformed with pHL Smy1-3GFP plasmid, which 
expresses Smy1p tagged with 3GFP under its own promotor. When I 
looked at these cells at room temperature under microscope, I found a 
bright cap at the bud tip in those small and medium budded cells. What’s 
more important, bright dots are constantly generated in the mother cell 
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and rapidly transported into the bud (Fig 2.1A). Later, when I double 
labeled Smy1p-3mCherry and GFP-Sec4, I found they co-localize 
(Fig2.1B). Taken together, these data suggest Smy1p is a passenger 
protein on secretory vesicles. 
 
Fig 2.1 Smy1p is a passenger protein on secretory vesicle.  
(A) Smy1p-3GFP in WT cells at RT.  
(B) Smy1p-3mCherry and GFP-Sec4p co-localize in WT cells at RT (white arrow 
points to a vesicle). 
 
2.2 Smy1p loses its localization in myo2, sec2 and sec4 mutants 
To answer the question what factors affect Smy1p localization, I decided 
to take advantage of the mutants that will separate Myo2p from 
secretory vesicles. First, I used myo2 tail conditional mutants, including 
myo2-12, myo2-14, myo2-16 and myo2-24. At room temperature, Sec4p 
staining in both myo2-12 and myo2-16 is largely depolarized (this 
research), while at restrictive temperature, the staining is totally diffuse 
(Schott et al., 1999). myo2-14 is rather special because it has a small 
truncation at the C-terminal which disrupts its interaction with Smy1p, 
but the Sec4p staining remains normal at room temperature. myo-24 has 
the same C-terminal truncation as myo2-14, but no other mutations 
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(From Dr. Irina Chernyakov), so that other factors can be excluded. In 
these mutants, I expressed Smy1p-3GFP and Sec2p-RFP as vesicle marker 
(Smy1p-3mCherry and GFP-Sec4p for myo2-12) to track their localization. 
As expected, at room temperature, in myo2-14 and myo2-24, Smy1p 
staining is diffuse while Sec4p remains polarized (Fig 2.2A), suggesting 
Myo2p binding is necessary for the correct localization of Smy1p. 
Surprisingly, although Myo2p is polarized, Smy1p is largely depolarized in 
myo2-12 and myo2-16 cells (Fig 2.2A, B and C). To investigate this result, 
later I performed a yeast two-hybrid experiment and found myo2-16 has 
a weakened interaction with Smy1p (Fig 2.2D). Therefore, Smy1p 
localization is highly sensitive to its interaction with Myo2p. However, for 
myo2-12, I still have no convincing answer. I would suggest that Smy1p 
interacts with Myo2p only on secretory vesicles, and Myo2p binding 
alone is not sufficient for Smy1p localization. 
In addition to that, I also studied the effect of sec mutants on Smy1p 
localization. Before, it was believed that Myo2p would always polarize by 
itself when it is detached from secretory vesicles. So in sec2-56 and 
sec4-8, which accumulate vesicles all over the cell at the restrictive 
temperature, I would be able to tell if Smy1p binds to Myo2p or the 
vesicles. The result was quite unexpected yet reasonable. At room 
temperature, Smy1p-3mCherry and Myo2p-3GFP are both well polarized. 
In contrast, in sec2-56 and sec4-8 cells, when shifted to 35 for 20min, 
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both Myo2p and Smy1p staining became diffuse (Fig 2.2E). This was the 
first time that we observed a depolarized Myo2p when actin structure is 
still intact (data not shown), which means that Myo2p probably needs an 
initiation step so that it can continue walking along actin cables, which is 
tightly related to the function of Sec4p. For Smy1p, again this is a strong 
evidence that Smy1p doesn’t bind to secretory vesicle but needs Myo2p 
to correctly localize. 
2.3 Smy1p truncations localize in various ways 
Smy1p has three domains: a head domain, a coiled-coil region and a tail 
domain. Previous data suggests the tail domain to be the Myo2 binding 
domain (MBD), and Smy1p truncation without this region lost its 
localization as well as function (Beningo et al., 2000). So it is intriguing to 
ask how each domain affects Smy1p localization. An easy strategy is to 
construct truncations with different combinations of domains and to 
study their localization respectively (Fig 2.3A).  
In total, I made 7 different truncations, under the control of the native 
promotor, tagged with 3GFP. The first thing I tested was if these 
constructs are functional or toxic. In myo2-16 smy1Δ + pRS316 SMY1 
cells, replacing the WT copy with any truncation construct by plasmid 
shuffling didn’t rescue the synthetic lethality. That means none of them  
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Fig 2.2 Smy1p localization in different mutants.  
(A) Smy1p-3GFP and Sec2p-RFP in WT, myo2-14, myo2-16 and myo2-24 cells at RT. 
Smy1-3GFP was expressed under its own promotor on a CEN plasmid. Smy1p 
localization is lost in myo2-14 and myo2-24, while Sec2p remains polarized. In 
myo2-16 both of them are depolarized. 
(B) Smy1p-3mCherry and GFP-Sec4p in myo2-12 at RT. GFP-Sec4p is expressed 
under the Yop1 promotor on a CEN plasmid. Smy1p-3mCherry is the same as the 
GFP version in A. Sec4p forms bright spots in the mother cell, indicating a 
secretion block. Smy1p staining is diffuse. 
(C) Smy1p and Sec4p polarization is quantified in myo2 tail mutants. Data were 
collected based on imaging of Smy1p-3mCherry and GFP-Sec4p. N=3.  
(D) Yeast two-hybrid to test the interaction between different myo2 cctail and Smy1p 
or Sec4p. WT cctail interact with Sec4p weakly and Smy1p strongly at all 
temperature. All tail mutants have lost their interaction with Sec4p, even when 
NLS-Smy1p is expressed (not verified due to lack of Smy1p antibody). myo2-14 
totally loses its interaction with Smy1p, while myo2-16 is partially affected (weak 
on 3DO at high temperature, no growth on 4DO).  
(E) Live imaging of Myo2p-3GFP and Smy1p-3mCherry in sec2-56 and sec4-8 cells 
at RT and 35. At restrictive temperature, both localizations are lost. 
Quantification is based on three independent experiment (N=3). Vesicle marker 
was not available here as Sec2p and Sec4p cannot be used. GFP-Snc1p and 
RFP-Snc2p were both too dim to give any clear vesicle staining. 
 
 
is fully functional as the WT allele. Also, expressing them doesn’t have 
any obvious effect on the cell growth in WT and myo2-16 cells (data not 
shown). With that clear, I expressed them in WT cells at room 
temperature, and found all of them showed different localization 
patterns (Fig 2.3B). Smy1p without its tail doesn’t localize to the bud tip 
as expected, but instead goes to the vacuole and presumably is degraded, 
as the staining is very dim. In comparison, Smy1p without its head 
hyperpolarizes to the bud, and forms bright aggregates. This effect can 
be seen even when the first coiled-coil (the coiled-coil region is predicted 
to have two CC) is deleted. However, when both coiled-coils are lost, 
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staining of the tail or MBD domain itself is all diffuse, indicating that just 
Myo2p binding is not enough. These truncations also have different 
expression levels, which will be covered in detail in the next chapter. In 
summary, Smy1p localization seems to be more complicated than we 
expected, with different domains contributing in different ways. 
 
 
Fig 2.3 Smy1p truncations localize in various ways. 
(A) Schematics of three domains of Smy1p: Motor-motor or head domain, 
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CC-coiled-coil region, MBD-Myo2p binding domain or tail. Truncations were 
constructed according to the map, expressed under its own promotor, tagged with 
3GFP 
(B) Smy1 truncations tagged with 3GFP visualized in WT cells at RT. 
2.4 Smy1p distribution by cell fractionation 
To further support my imaging data, cell fractionation experiments and 
western blot analysis were employed. The idea is that, since Smy1p 
localization is lost in myo2-14 and myo2-16 cells, maybe I can quantify 
this effect by monitoring the distribution of the protein on different 
membrane components. Although the result was not as expected, I feel 
it necessary to put these data in the thesis because I spent a lot of time 
in refining the system. 
In this experiment, I tagged endogenous Smy1p with 3HA using the 
Longtine cassette (Longtine et al., 1998) in WT, myo2-14 and myo2-16 
cells, because we didn’t have Smy1p antibody at that time. After 
fractionation, theplasma membrane, ER and other large membrane 
compartments precipitate in the “P13” fraction, while “P100” mainly 
represents secretory vesicles. Sec4p was shown to distribute almost 
equally between these two fractions (Goud and Salminen, 1998), which 
was confirmed in my experiments. In addition, this localization can be 
disrupted by adding 1% Triton X-100. However, although Smy1p 
distribution is very similar to Sec4p, it remains in the “P100” fraction 
after 1% Triton X-100 is added (Fig 2.4). No obvious difference was found 
between the three strains used. In conclusion, this experiment is hard to 
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interpret since the fractionation is quite rough.  
 
Fig 2.4 Smy1p stays to membrane fractions. 
This Western was done by blotting with Myo2p antibody and then stripped to blot 
with anti-HA and anti-HA antibody. The image were cut and put together because 
some lanes were empty due to loading mistake. Sec4p mainly distributes to membrane 
fractions while Myo2p doesn’t. However, Smy1p stays in P100 fractions in all 
mutants and even after Triton X-100 was added. 
Conclusion and Discussion 
In this chapter, I mainly investigated how Smy1p localization is achieved. 
The Trybus group proposed an electrostatic tether model, claiming 
Smy1p binds to secretory vesicles rather than Myo2p. My data clearly 
shows that Myo2p binding is necessary for Smy1p localization, because 
when this binding is lost, as in myo2-14 and myo2-24, or weakened, as in 
myo2-16, Smy1p is mislocalized. However, this interaction is not 
sufficient either, due to the fact that in myo2-12 and myo2-16, Myo2p is 
polarized but Smy1p is not. Besides that, I also studied Smy1p 
localization in sec2-56 and sec4-8 cells, which have depolarized Myo2p, 
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Smy1p and vesicles at the restrictive temperature. Because no good 
secretory vesicle marker was available here (GFP-Snc1p and RFP-Snc2p 
are both too dim), I couldn’t tell if Smy1p and Myo2p stayed on secretory 
vesicles. However, by careful studying the fluorescence of Myo2p-3GFP 
and Smy1p-3mcherry, I didn’t see any dots or blobs, but only diffuse 
staining. I would infer that Myo2p and Smy1p are both in the cytosol 
under these conditions. To further confirm that, immuno-fluorescence 
microscopy using anti-Sec4p and anti-Smy1p antibody is needed.  
Taken together, Smy1p binds to secretory vesicles through binding to 
Myo2p, but this interaction cannot be maintained when Myo2p is 
detached, presumably because Smy1p also interacts with something else 
on secretory vesicle. 
I also tried to determine the localization-determining domain of Smy1p, 
but the result was quite complicated. There seems to be a balance 
between the head and the tail domain, because without the tail the 
protein is degraded, while without the head the protein is 
hyperpolarized and aggregated. The coiled-coil (CC) regions are also very 
important since the head or tail by itself doesn’t localize in the same way 
as when combined with CC. I will talk more about these truncations in 
the following chapter. I believe in these findings lies the molecular 
mechanism of Smy1p function. Further investigation is definitely needed. 
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CHAPTER 3: SMY1P EXPRESSION LEVEL 
Introduction 
For decades, Smy1p research has been focused on its genetic and 
physical interaction, as well as its localization. However, the molecular 
mechanism how this protein functions remains elusive. An interesting 
observation from my localization experiment of Smy1p truncations was 
that they all localizes in different ways. For example, Smy1p without the 
motor domain (Smy1DM) tagged with 3GFP forms extremely bright spots, 
while the fluorescence of Smy1p without the tail domain (Smy1DT) 
tagged with 3GFP almost cannot be seen (mostly in vacuole). This 
phenomenon inspired me to ask whether they have different expression 
levels. In addition, how is this expression level controlled?  
Material and Method 
Molecular cloning and vectors 
Cloning techniques are the same as described in Chapter 2. Vectors used 
include pHL-Smy1-truncation-3GFP series, pRS415 prom HA-Smy1-6his, 
pRS415 prom UBI-R-HA-Smy1-6his, pRS415 prom UBI-M-HA-Smy1-6his, 
(prom is a weakened GAL promotor), pE-SUMO-Smy1 and the Longtine 
3HA plasmid. 
Immunoblots 
Cells were grown to mid-log phase in 5ml liquid culture and the OD600 
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was measured. After that, I spun down the cells at 1,000 rpm and 
washed them once with distilled water. Then the cells were transferred 
to 1.5ml tubes and resuspended in ice chilled 1X SDS loading buffer (40ul 
for each OD unit, i.e. 200ul for 5ml OD=1 culture), so that all samples are 
normalized to the same cell density. Following that, the same volume of 
ice chilled glass beads were added to each tube. The tubes were 
vortexed for 1min three times with 1min ice-cooling between each 
vortex. At last these samples were boiled for 5min, and spun down in 
clinical centrifuge at 13,000 rpm for 1min. The resulting supernatant was 
used for SDS-PAGE and western-blot. 
Smy1p expression and purification 
BL21 (DE3) competent bacteria was transformed with the 
pE-SUMO-Smy1 plasmid and selected on LB+Amp plates. A single colony 
was picked and grown in 5ml LB overnight, expanded to 1L the next day. 
When the OD600 reached ~0.5, I added 0.05% IPTG (500ul of 1000X stock) 
and induced overnight at 18. After 12 to 16h induction, cells were 
collected and resuspended in 50ml cold Binding Buffer (PBS pH7.5, 5% 
glycerol, 20mM imidazole) with protease inhibitor. Then the paste was 
sonicated (button-tip 5x30sec 50% duty cycle, output level 4-5) until the 
lysate was clear, and spun down at 12,000 rpm for 20min at 4During 
the spin I equilibrated Cobl column (2ml Talon beads) with 10 column 
volume (cv) of Binding Buffer. Triton X-100 was added to 1% to the 
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supernatant, which was then carefully loaded into the Cobl column. 
Flow-through was collected for a gel sample. I washed the column with 
20cv of Binding Buffer, then eluted with 3cv of Binding Buffer, followed 
by another elution (collect separately) with 3cv of Elution Buffer (binding 
buffer+300mM imidazole). Elution (elution1+2) was dialyzed in 2X 500mL 
of Binding Buffer overnight. Dialyzed protein was transferred to falcon 
tube with ~35-60ul of Ulp1 added per 500mL culture, incubated at 30°C 
for 40min to cleave SUMO tag. Then I poured 1ml Cobl column and 
equilibrated it with 10mL Binding Buffer. Cleaved protein was poured 
over the column and flow-through was collected. At last, I washed the 
beads with 1mL Binding Buffer and combined the two elutes. Protein 
was concentrated with 20% glycerol added, and frozen at -80. 
Yeast synchronization 
I used the α-factor release protocol (L. Breeden et al., 1997) to 
synchronize the yeast cells. Basically, cells were grown in 5ml liquid 
medium to early-log phase (OD600=0.2~0.3). α-factor was added to 1X 
(200X stock is 1mg/ml). After 2h, I looked at the cells under light 
microscope to make sure they are arrested as round cells (G-1). Then, I 
washed the cells with the same volume of water for three times and 
resuspended them in the same volume of medium to resume growth. 
500ul samples were taken every 15min for 2h. Cells would remain 
synchronized for ~2 generations. 
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Results 
3.1 Smy1p protein level is cell-cycle independent 
The first question we asked is whether the Smy1p protein level changes 
according to cell cycle. Here, I took advantage of the WT strain in which 
endogenous Smy1 is tagged with 3HA I made previously. Then I used 
α-factor release to synchronize the cells, and confirmed the effect by 
microscopy (Fig 3.1A). After that, Smy1p protein level was monitored 
every 15 min for 2.5h by WB with anti-HA antibody. The result showed 
that Smy1 level is cell-cycle independent (Fig 3.1B) 
 
Fig 3.1 Smy1p level is cell-cycle independent. 
(A) Cells were synchronized after α-factor release, and gradually went through the 
cell cycle in 2h 
(B) Smy1p level were monitored by anti-HA WB, which doesn’t change according to 
cell cycle. Tpm1/2 was used as loading control here. 
3.2 Smy1p truncations have different expression levels 
As mentioned in the introduction of this chapter, I started to pay 
attention to the expression level of different truncations shortly after the 
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imaging experiment. I used anti-GFP WB since they were all tagged with 
3GFP and expressed under the native SMY1 promotor. The result is quite 
interesting (Fig 3.2A). As you can see, full-length Smy1p expresses at a 
rather low level. When the motor domain is deleted, the expression level 
suddenly rose more than 10 times (DM, DM+cc1 and Tail), which 
explains why the staining of these proteins were so bright. When the tail 
domain is truncated, the expression dropped to an extremely low level 
(DT), which is dependent on the CC domain because the motor domain 
itself could still be detected. Consistent with the observations, 
Smy1DT-3GFP was extreme dim and mostly found in the vacuole, 
probably undergoing degradation. The CC region itself seems to be not 
so important because the protein level remain almost the same as FL 
when it is deleted. 
To further investigate the regulation of Smy1p expression level, I also 
chased the protein by expressing it under GAL promotor and shutting 
down the expression by shifting to glucose medium. WT cells carrying 
the pRS415 prom Smy1-6his plasmid, which expresses Smy1p-6his under 
a weakened GAL promotor, were grown in Sraff+0.5% galactose medium 
overnight to mid-log phase. Then cells were aliquoted into two tubes, 
washed once with water, resuspended either in the same medium or in 
glucose medium. Smy1p level stays almost the same in the 2h chase. 
Therefore, Smy1p doesn’t undergo quick turn-over (Fig 3.2B). 
 35 
 
 
Fig 3.2 Smy1p truncation expression level and protein turn-over 
(A) Cells expressing different Smy1p truncations were subjected to anti-GFP WB. 
Tpm1/2 is loading control. FL:full-length Smy1p. DT: Smy1p without tail 
domain. DCC: Smy1p without coiled-coil region. DM: Smy1p without mothr 
domain. DM+CC1: Smy1p without motor and first CC. M: Motor domain. CC 
coiled-coil region. Tail: tail domain. These constructs were all tagged with 3GFP. 
(B) Same amount of cells were loaded to each lane. Western blots was performed 
using anti-6his antibody.. 
3.3 Smy1p is subject to post-translational modification 
Smy1p protein is very curious not only because of the complicated 
expression level regulation, but also due to its unexpected behavior in 
another experiment, which will be covered in detail in the next chapter. 
Luckily, through an accidental experiment I solved this problem. In this 
experiment, WT cells were transformed with pRS415 prom HA-smy1-6his, 
pRS415 prom UBI-M-HA-smy1-6his or pRS415 prom UBI-R-HA-smy1-6his. 
These plasmids express HA-Smy1p-6his or N-terminal ubiquitin tagged 
HA-Smy1p-6his under a weakened GAL promotor. The ubiquitin tag here 
is used to expose the first amino acid of the fusion protein, which is 
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either methionine (M) or arginine (R). M is supposed to make this 
protein very stable and R would induce degradation (Park et al., 1992). I 
grew the cells in SRaff-Leu medium until mid-log phase and then induced 
the expression with 2% galactose for 4h. WB using anti-HA and anti-6his 
antibody were performed. Surprisingly, I can only detect the full-length 
protein with anti-6his antibody but not anti-HA antibody. Besides, I could 
see two bands for M construct but only one band for R construct (Fig 
3.3). Therefore, the beginning few amino acids of Smy1p head are 
probably cleaved in the cell. 
 
Fig 3.3 Smy1p undergoes post-translational modification 
WT: HA-Smy1p-6his. M: UBI-M-HA-Smy1p-6his. R: UBI-R-HA-Smy1p-6his. The 
upper band is the fusion protein. The lower band is the mature form Smy1p-6his. 
3.4 Smy1p antibody generation 
Generating a Smy1p antibody is very important for the following 
research in the lab. So I expressed his-SUMO-Smy1p in bacteria and 
purified the untagged Smy1p according to the protocol in the material 
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and methods. To enhance the efficiency I repeated passing the 
flow-through, eluting the protein and regenerating the column for 3 
times. Each time the protein able to bind to column decreased. At last I 
combined the three elutes and digested the His-sumo-Smy1p protein 
with Ulp1p. A SDS-PAGE was used to confirm the success of purification. 
You can see the digested untagged Smy1p is indeed a little bit smaller 
than the tagged one (Fig 3.4A). After that, I did a gel prep to further 
purify the protein and got 1ml Smy1p protein (~0.8mg/ml) for antibody 
generation (Fig 3.4B). 
 
Fig 3.4 Smy1p purification 
(A) 6his-SUMO-Smy1p was purified using the Cobl column.  
(B) After the gel prep, I measured the concentration of Smy1p using BSA as standard. 
The Smy1p band is approximately 0.8 mg/ml.  
 
Conclusion and Discussion 
In this chapter, I started my investigation of Smy1p expression level by 
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chasing it through the cell cycle. Some adaptor proteins like Vac17p, part 
of the vacuole receptor for Myo2p, are tightly controlled according to 
cell cycle because the transport must happen in a timely and orderly way. 
Unfortunately, Smy1p level doesn’t change with cell cycle, which is 
reasonable, because polarized secretion is constantly needed, unlike 
vacuole segregation.  
Then how is Smy1p level controlled? Interestingly, different domains 
seem to have different effects. The tail domain stabilizes this protein, for 
the tail itself expresses at a high level. In contrast, the head domain 
antagonizes the tail, making the protein very unstable. However, only 
when the head or the tail is combined to the coiled-coil region could the 
effect be exaggerated, because Smy1p without its head domain forms 
aggregates in the bud while Smy1p without tail is quickly degraded in 
vacuole. Therefore, there seems to be an inner balance for Smy1p to 
make the choice of being degraded or to accumulate. And this balance 
may be very important for us to understand Smy1p function, as to how 
Smy1p is loaded onto secretory vesicles and how it is recycled back to 
the mother cell.  
What’s more, Smy1p seems to be post-translational modified, with the 
head domain clipped, although the mature protein is quite stable. To 
verify this, N-terminal GFP tagged Smy1p can be used and the 
fluorescence can be monitored. If this modification does happen in vivo, 
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the GFP signal should be diffuse. Furthermore, where this cleavage 
occurs and why it is needed is still unclear. One easy way to answer this 
question is to purify Smy1p-6his from yeast cells using Cobl column and 
send the protein for mass-spec, in order to determine the exact cleavage 
site. Once the site is known, mutants with a disrupted cleavage site can 
be generated, whose function and localization would be interesting for 
investigators. 
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CHAPTER 4:SMY1P DEPLETION IN DIFFERENT MUTANTS 
Introduction 
Genetic approaches have been playing an important role in our research 
for a long time. Budding yeast is very useful and convenient for genetic 
study, because it has a haploid and a diploid form. As haploid, the 
genome can easily be modified and the effect of the modification can 
readily be detected. Through mating and tetrad-dissection, different 
mutations can be combined to study synthetic effects, which would 
provide us with hints of the protein’s function.  
Previous research has clearly put Smy1p in a genetic interaction network, 
which is shown in Table 1 (adopted from SGD). As you can see, Smy1p 
seems to be involved in many processes, in which three aspects are 
especially prominent. First, Smy1p interacts with various genes 
regulating actin cytoskeleton assembly, including BEM1, BEM2, BUD14, 
CLA4, BNR1, BNI1 and PFY1. From this perspective, as stated previously, 
the Goode group proposed Smy1p to be a Bnr1p suppressor. Second, 
Smy1p seems to also functions in cytokinesis, because it has synthetic 
effects with BCK1, BUB1, CDC11, CDC12, CDC3, HOF1, MYO1 and SHS1, 
which are all related to bud neck formation. However, for now not much 
attention has been put in this area. Third, Smy1p is clearly implicated in 
late secretion, as SEC2, SEC4, MYO2, CHS5 and SNC2 all interact with it 
genetically. Smy1p also interacts with Myo2p physically, which is the only 
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interaction I have confirmed right now. One group claimed that Smy1p 
interacts with Bnr1p, but their two-hybrid data was not satisfactory 
(Kikyo et al., 1999). Sec2p was also claimed to interact with Smy1p 
(Zhang et al., 2009), but I couldn’t verify that by Y2H myself. In this 
research, I am focusing on this aspect.  
Table 3.1 Smy1p genetic interaction 
 
Gene Description Interaction 
ADH1 Alcohol dehydrogenase Negative (high-throughput) 
AIM44 Protein of unknown function Negative (high-throughput) 
BCK1 MAPKKK acting in the protein 
kinase C signaling pathway 
Synthetic Rescue (manual currated) 
Negative (high-throughput) 
BEM1 Protein containing SH3-domains Negative (high-throughput) 
BEM2 Rho GTPase activating protein 
(RhoGAP) 
Synthetic Lethality 
BNI1 Formin smy1 bud14 bni1 is synthetic lethal 
at high temperature 
BNI4 Targeting subunit for Glc7p protein 
phosphatase 
Negative (high-throughput) 
BNR1 Formin smy1 bud14 bnr1 is synthetic rescue 
at high temperature 
BUB1 Protein kinase involved in the cell 
cycle checkpoint into anaphase 
Synthetic Lethality 
(high-throughput) 
BUD14 Protein involved in bud-site 
selection 
Synthetic Growth Defect 
CDC11 Component of the septin ring that is 
required for cytokinesis 
Negative (high-throughput) 
CDC12 Component of the septin ring that is 
required for cytokinesis 
Negative (high-throughput) 
CDC3 Component of the septin ring that is 
required for cytokinesis 
Negative (high-throughput) 
CDC34 E2 enzyme and catalytic subunit of 
SCF ubiquitin ligase complex 
Synthetic Lethality 
CHS3 Chitin synthase III Synthetic Growth Defect 
(high-throughput) 
CHS5 Component of the exomer complex Synthetic Growth Defect 
(high-throughput) 
CHS7 Protein of unknown function Synthetic Lethality 
(high-throughput) 
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CLA4 Cdc42p-activated signal transducing 
kinase of the PAK family 
Synthetic Lethality 
(high-throughput) 
CMD1 Calmodulin Negative with cmd1 mutant 
(high-throughput) 
DRS2 TGN aminophospholipid translocase 
(flippase) 
Synthetic Growth Defect 
(high-throughput) 
DUN1 Cell-cycle checkpoint 
serine-threonine kinase 
Negative (high-throughput) 
ELM1 Serine/threonine protein kinase that 
regulates cellular morphogenesis 
Negative (high-throughput) 
GIM4 Subunit of the heterohexameric 
cochaperone prefoldin complex 
Negative (high-throughput) 
HOF1 Bud neck-localized, SH3 
domain-containing protein required 
for cytokinesis 
Negative (high-throughput) 
ILM1 Protein of unknown function Negative (high-throughput) 
KIN3 Nonessential serine/threonine 
protein kinase 
Negative (high-throughput) 
MNN10 Subunit of a Golgi 
mannosyltransferase complex 
Negative (high-throughput) 
MYO1 Type II myosin heavy chain Synthetic Growth Defect 
(manually curated) 
MYO2 Myosin V Synthetic Lethality and Rescue 
(manually curated) 
PFY1 Profilin Dosage Rescue 
PHO85 Cyclin-dependent kinase Synthetic Growth Defect 
(high-throughput) 
SEC2 GEF for Sec4p Synthetic Lethality 
SEC4 Small GTPase Synthetic Lethality 
SHS1 Component of the septin ring that is 
required for cytokinesis 
Negative (high-throughput) 
SKT5 Activator of Chs3p Negative (high-throughput) 
SLA1 Cytoskeletal protein binding protein Synthetic Growth Defect 
(high-throughput) 
SLT2 Serine/threonine MAP kinase Negative (high-throughput) 
SNC2 v-SNARE Negative (high-throughput) 
SSD1 Translational repressor with a role in 
polar growth and wall integrity 
Negative (high-throughput) 
SWI3 Subunit of the SWI/SNF chromatin 
remodeling complex 
Negative (high-throughput) 
SWI4 Subunit of the SWI/SNF chromatin 
remodeling complex 
Negative (high-throughput) 
VPS4 AAA-ATPase involved in Phenotypic Suppression 
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multivesicular body protein sorting (high-throughput) 
YDJ1 Type I HSP40 co-chaperone 
involved in regulating HSP90 and 
HSP70 
Negative (high-throughput) 
 
Despite all these pieces of evidence, a fundamental problem is how do 
we interpret them and uncover the molecular mechanism behind it. As a 
way to investigate this problem, I conducted a series of experiment to 
observe the synthetic effect of Smy1p depletion in myo2, sec2 or sec4 
conditional mutants. 
Material and Method 
Molecular cloning and vector construction 
Cloning techniques are as stated previously. Vectors used are: pRS415 
prom (prom is a weakened GAL promotor), pRS415 prom 
UBI-M-smy1-6his, pRS415 prom UBI-R-smy1-6his. Yep351 SMY1 (2u), 
pRS316 SMY1, pRS416 GFP-SEC4, pRS416 GFP-SNC1, pRS303 sec2-56, 
pRS303 sec4-8 
Gene knockout 
Gene knockout was done using homologous recombination. Genomic 
DNA was extracted using the genomic DNA kit (Zymo Research) from the 
appropriate deletion collection strains. PCR was used to amplify the Kan 
cassette at the locus to be deleted. Then, the 2ul PCR product 
(~200ug/ul) was transformed into 5ml culture of yeast cells, using the 
Li-Ac protocol. Transformants were selected on YPD + G418 plates. 
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Colonies were picked and genomic DNA was extracted. A verifying PCR 
was done to make sure that the locus was successfully deleted. 
Smy1p depletion 
In this experiment, endogenous SMY1 was deleted and Smy1p 
expression solely relies on the plasmid pRS prom UBI-R-smy1-6his. The 
cells were grown in Sraff-leu-ura +0.5% galactose medium overnight to 
reach mid-log phase. Then the cells were centrifuged at 1,000 rpm for 
5min and washed once with distilled water. After that, they were 
resuspended in either the same medium or SD-leu-ura medium to grow 
for another 16h. At last, the cells were visualized under the fluorescence 
microscope.  
Actin staining 
Cells grown in 5ml liquid medium to the required density were fixed by 
adding 600ul 37% formaldehyde for 5min. Then the cells were pelleted 
and resuspended in 4.5ml 1XPBS+500ul 37% formaldehyde to fix for 
another 25 min. After that, cells were washed with 1XPBS three times to 
get rid of the formaldehyde (this is vital). Then they were transferred to 
1.5ml tubes and resuspended in 200ul 1XPBS+20ul Alexa-568 phalloidin 
(1% Triton X-100 may be added), kept in dark for 1h with occasional 
vortexing. At last, these cells are washed four times with 1ml 1XPBS and 
subject to microscopy. 
Results 
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4.1 Smy1p overexpression still suppresses myo2-16 when either 
BNR1 or BNI1 is deleted 
The Goode group claimed that Smy1p is a negative regulator of the 
formin Bnr1p, which localizes to bud neck. Indeed, Smy1p was shown to 
possibly be involved in actin cytoskeleton regulation. However, this 
model cannot explain why Smy1p overexpression, which presumably 
reduces the number and length of actin cables in the mother cell, could 
suppress myo2 head and tail conditional mutants. Therefore, I set out to 
explore whether this phenotype is related to formins. 
bnr1Δ myo2-16 and bni1Δ myo2-16 double mutants were made as 
described in material and methods. In this experiment, myo2-14, 
myo2-16, bnr1Δ myo2-16 and bni1Δ myo2-16 were transformed with 
Yep351 SMY1 (2u) or an empty vector. The growth of these strains was 
tested by a 5X serial dilution assay at 26℃ and 32℃. As you can see (Fig 
4.1), temperature sensitivity (TS) of myo2-14 cannot be suppressed by 
multi-copy SMY1 while myo2-16 can. When either BNR1 or BNI1 was 
deleted in myo2-16 cells, the TS phenotype could still be suppressed by 
overexpressing Smy1p. Therefore, Smy1p’s function in late secretion is 
not related to formins. 
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Fig 4.1 Smy1p overexpression still suppresses myo2-16 temperature sensitivity 
when either Bnr1p or Bni1p is lost. myo2-14 is used as a negative control here, 
which we knew cannot be suppressed by multi-copy SMY1. 
 
4.2 Smy1p depletion in myo2-16 causes a block in secretion 
myo2 tail conditional mutants generated in our lab were found to be 
synthetic lethal with smyΔ (Schott et al., 1999). Similarly, SMY1 becomes 
essential in sec2, sec4 and other conditional mutants. These genetic data 
prompted us to investigate Smy1p function in polarized secretion. 
However, why these genetic interactions exist or how these double 
mutants lost the ability to survive is very curious, and the phenotype 
would be even more informative for our research. The first idea may be 
to generate some temperature sensitive (TS) mutants, but myo2, sec2 
and sec4 mutants are already TS. As a result, I decided to try to solve this 
problem by depleting Smy1p and observing the phenotype. 
The method (Park et al., 1992) is to replace the endogenous SMY1 allele 
with an easily degraded SMY1 copy controlled by the GAL promotor (Fig 
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4.2A). Upon shifting to glucose medium, the expression is shut down and 
the protein is quickly degraded, so that the synthetic effect can be 
monitored. I successfully constructed all the plasmids needed and 
verified that the new Smy1p allele is functional (Fig 4.2B). However, this 
allele was not quickly degraded as expected, but maintained a quite low 
level (Fig 4.2C). The reason for that was stated in the previous chapter 
(Fig 3.3). N-terminal of Smy1p is processed in the cell, which also takes 
off the ubiquitin tag that destabilizes the protein. This modification likely 
happens slowly or the efficiency was decreased due to the N-terminal 
tag, because most of the protein is quickly degraded, with only a small 
amount of mature form left. This small portion of Smy1p is enough to 
support cell growth, and it is stable for at least 6h. Despite that, I 
decided to try this method by waiting for 16h for the protein to be 
naturally diluted.  The result was quite interesting (Fig 4.2D). When 
Smy1p is depleted in myo2-16 smy1Δ cells, the cell accumulates 
secretory vesicles in the mother cell, especially at the bud neck. This has 
also been seen in other mutants like myo2-12 and myo2-16 at high 
temperature, indicating a secretion block. As a control, actin staining was 
included to exclude the possibility that the secretion block was caused by 
disrupted actin cytoskeleton. 
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Fig 4.2 Smy1p depletion in myo2-16 
(A) Schematics of plasmids used and strain generation Smy1p was N-terminal 
tagged with first an ubiquitin, followed by a methionine or arginine, then a 
fragment from bacteria LacIq. When the protein is expressed, it will soon be 
deubiquitinated so the first amino acid after ubiquitin will be exposed. Arginine 
will destabilize the protein while methionine does the opposite. The LacI 
fragment contains two lysines which can be ubiquitinated. Together, the 
R-construct will be sent to the proteasome for degradation quickly.  
(B) UBI-R-smy1-6his is able to replace the endogenous SMY1 in myo2-16. 1 is 
a positive control since the endogenous SMY1 is intact. 2, 3 and 4 are expressing 
different Smy1p constructs, which could complement the smy1 deletion when 
induced on SGAL plates, and suppress the synthetic lethality. 
(C) Smy1p construct degradation. WT cells expressing different Smy1p 
constructs were grown in Sraff+2%galactose medium overnight and shifted to 
either the same medium or SD medium. Protein levels were monitored by 
anti-6his WB for 6h. Due to the N-terminal processing of Smy1p, you can see 
two bands for UBI-M-smy1-6his. UBI-R-smy1-6his has only one band and 
expresses at very low level, but is stable for 6h. 
(D) Smy1p depletion in myo2-16 causes a secretion block. After 
UBI-R-smy1-6his expression is shut down for 16h, myo2-16 smy1∆ accumulate 
secretory vesicles in the mother cell, especially at the bud neck, while actin cables 
are intact. GFP-sec4 was used as vesicle marker. 
 
I have also planned to conduct the same experiment in sec2-56, sec2-59 
and sec4-8 cells. I constructed pRS303 sec2-56, pRS303 sec2-59 and 
pRS303 sec4-8 plasmids, and transformed them into WT BY strain to 
generate the sec2-56, sec2-59 and sec4-8 mutants in the BY background, 
because BY strain is believed to be healthy and it is GAL+. I have also 
sequenced the strains and verified the temperature sensitivity 
phenotype. However, I didn’t have time to carefully refine the system.  
Conclusion and Discussion 
In previous research, genetic approaches were widely employed and 
provided us with plenty of hints to understand the function of proteins 
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encoded by different genes. High-throughput methods like SGA largely 
expanded our ability to study genetic networks, although not all the data 
are reliable. Smy1p was shown to be involved in a lot of processes 
related to polarity establishment. Actin cytoskeleton assembly, in which 
formins play an important role, was one area that Smy1p could influence. 
However, whether this activity is related to its function in secretion was 
unclear. Through my experiments, we found that deleting either formin 
doesn’t affect Smy1p’s suppression of the myo2 conditional mutant 
myo2-16. More conditional mutants may be used to further support the 
idea that Smy1p has a separate function in secretion.  
What’s more important, the result from the Smy1p depletion experiment 
is the first direct evidence that Smy1p is really related to secretion. 
Although the construct I used didn’t work as expected, a 16h shift still 
gave us a very strong phenotype. These accumulated secretory vesicles 
suggest that when Smy1p is lost, mutant Myo2p cannot transport its 
cargo. Therefore, Smy1p seems to play an accessory role that helps 
Myo2p to move vesicles, but we still don’t know how Smy1p functions. 
One possibility is that, without Smy1p, mutant Myo2p cannot stay 
attached to secretory vesicles due to weakened interaction with Sec4p. It 
would be very interesting to look at Myo2p localization when Smy1p is 
depleted. I did try to do this using immuno-fluorescence with 
anti-Myo2p tail antibody, but the experiment didn’t work well. Besides 
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that, the same experiment can also be tried in sec2 and sec4 conditional 
mutants. The fundamental problem of these mutants is that Sec4p stays 
in the GDP-bound form most of the times, reducing its ability to recruit 
and activate Myo2p. With Smy1p, this is possible at permissive 
temperature. Without Smy1p, this initiation step probably cannot 
happen. That’s why sec2-56 and sec4-8 are synthetic lethal with smy1Δ. 
If we can look at secretory vesicle and Myo2p localization in these 
conditions, maybe a new model of Smy1p function in late secretion can 
be established.  
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CHAPTER 5: SMY1 MUTANTS IN MYO2 SENSITIZED 
BACKGROUND 
Introduction 
Smy1p is a non-essential gene, which means any mutation of Smy1p 
would hardly have any effect on the cell. However, to study molecular 
mechanism of a protein’s function, mutational analysis is indispensable. 
Therefore, one can only try to study the synthetic effect of smy1 
conditional mutants in a strain where SMY1 is essential. We call this kind 
of strain a “sensitized strain”. There are a lot of sensitized strains for 
Smy1p, as shown in Table 3.1, but most of them are not usable because 
the strains are already temperature sensitive. So we set out to generate 
non-temperature-sensitive sensitized strains and then to generate smy1 
conditional mutants in those backgrounds.  
Material and Method 
Vectors 
p22 SMY1, pRS316 SMY1, pRS303 myo2 tail mutant library, pRS304 smy1 
mutant library, pGADT7 Myo2-cctail of 17 myo2 tail mutants I identified, 
pGADT7 WT Myo2-cctail, pGADT7 vector, pAS2 Smy1, pBridge Sec4ΔC, 
pBridge Sec4ΔC +NLS-Smy1, pRS416 GFP-sec4, pRS316 MYO2 and 
Yep351 SMY1. 
Synthetic lethal screen 
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This experiment was performed as previously described (Drain and 
Schimmel, 1988). I transformed smy1Δ ade2Δ ade3Δ strain (CUY30 
background) with p22 SMY1, which carries ADE3 gene and makes the 
colony red. This strain will sector on 1/5ADE SC plates, because SMY1 is 
not essential and when the plasmid is lost the colony becomes white. I 
grew the transformed strain to OD600=0.8 in –His medium, so that all the 
cells carry the plasmid. Then I took 1ml of culture and added 30ul EMS (3% 
final), let the tube sit at RT for 30min with vortexing every 10min. After 
that I spun down the cells at 5,000 rpm for 5min in a clinical centrifuge, 
and washed the pellet with 1ml 12% sodium thiosulfate to inactivate 
EMS, followed by three washes with 1ml ddH2O. At last, the cells were 
resuspended in 1ml H2O and diluted 1:1000 in YPD. I spreaded 100ul 
diluted cells onto SC 1/5ADE, which were then incubated at 30℃ for 
2days and at 4℃ for 3 days. Any colonies showing sectoring phenotype 
will be picked. 
Error-prone PCR and library construction 
The protocol for error-prone PCR is as described (Cadwell and Joyce, 
1992). The key to get a low mutagenesis rate is to lower the manganese 
concentration. The buffer system I used is as follows: 
 stock final concentration volume (ul) 
template 60ng/ul 6ng/ul 15 
F-primer 10uM 0.2uM 6 
R-primer 10uM 0.2uM 6 
dCTP 100mM 1mM 3 
dTTP 100mM 1mM 3 
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dATP 10mM 0.2mM 6 
dGTP 10mM 0.2mM 6 
Taq PCR buffer 10X 1X 30 
MgCl2 25mM 2.5mM 30 
MnCl2 (add last) 20mM 0.15mM 2.25 
Taq polymerase 5U/ul 0.05U/ul 3 
Tween 20 1% 0.05% 15 
BSA 10ug/ul (10X) 0.1ug/ul 30 
ddH2O   144.75 
Total   300 
After mixing the 300ul reaction, I aliquoted them into 6 tubes and ran a 
PCR at 50 for 10 cycles. The mutagenesis rate was about 0.67/1000nt. 
For smy1 mutagenesis, I first constructed the pRS304 SMY1 plasmid, 
which carries the WT SMY1 gene and can be linearization by BamHI 
digestion. Then I used this plasmid as template, and F-smy1-inte as 
forward primer, R-smy1-inte3 as reverse primers in the error-prone PCR 
to generate the mutagenized smy1 insert. Following that, to make a 
library, I digested the mutagenized smy1 insert and the pRS304 SMY1 
plasmid with NotI and XhoI, and ligated them together. When 
transforming bacteria with the ligation reaction, I made sure more than 
10,000 colonies were grown on LB+Amp plates. Then all the colonies 
were collected and cultured in 500ml LB+Amp liquid media for 2h at 
37. At last, a maxi-prep was performed for these bacteria and the 
resulting plasmid would be a mutant library. 
Mutant screen 
All screens were done by manually picking the colonies and 
resuspending them in 150ul of ddH2O in 96-well plates. Then, 5ul of the 
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mixture was spotted onto multiple plates to test different conditions. 
Strains that showed different growth were picked, streaked to single 
colonies and tested again. Only those showing the same phenotypes 
were kept and sequenced. 
Results 
5.1 Screen for myo2 sensitized strains 
To screen for sensitized strains, I chose to start with myo2 mutants first, 
because Smy1p is tightly related to Myo2p function and we know Smy1p 
interacts with Myo2p both physically and genetically. To mutagenize 
MYO2, two methods were employed: EMS random mutagenesis and 
error-prone PCR mutagenesis.  
The EMS random mutagenesis was done in my rotation, in a 
colony-sectoring screen (Koshland et al., 1985) searching for genes that 
are synthetic lethal with smy1Δ. The screen itself was not very successful 
since I only found three mutant strains. Fortunately, when I transformed 
another copy of MYO2 into these strains, two of them could be 
suppressed, suggesting that there may be recessive mutations at the 
MYO2 locus. Indeed, when I sequenced the MYO2 gene, two myo2 head 
mutants were found. One of them, named myo2-209, has a single point 
mutation in the head domain (nt: 2090 C to T, aa: 697 T to I). The other 
one of them, called myo2-247, also has a single point mutation in the 
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head domain (nt: 247 G to A, aa: 83E to K). As for phenotype, both 
mutants are not sensitive to heat (viable at 37) but grow slowly. The 
doubling time of myo2-209 is about 4h, while myo2-247 doubles roughly 
in 3h.  
Another way to generate sensitized strains is to use error-prone PCR and 
construct a mutant library, which will directly mutagenize the region of 
gene when transformed. Here I took advantage of an existing library of 
myo2 tail mutants (from Dr. Irina Chernyakov). This mutant library is 
based on the pRS303 vector, which mutagenizes only the tail region 
(aa1093 to aa1574) of MYO2 gene and linked it to a HIS3 marker. I 
transformed this library into the smy1Δ + pRS316 SMY1 strain (BY MATa), 
and got ~200 colonies/plate with 20 plates. After that, I manually picked 
~2,500 colonies and spotted them onto –HIS and –HIS+5-FOA plates, 
incubated at 26 for 3 days. 33 candidates that didn’t grow on –HIS 
+5-FOA plates were found, streaked to single colonies and tested again. 
At last, 17 mutants were left, from which genomic DNA were extracted 
and the smy1 locus was amplified by PCR then sequenced (Table5.1). All 
the mutants, except for myo2-48, are not temperature sensitive. I also 
cloned these mutants onto the pRS303 MYO2 tail plasmid and 
transformed them back to the starting strain smy1Δ + pRS316 SMY1 
strain (BY MATa). For every transformation I picked 3 colonies and 
spotted them on –His and –His +5-FOA plates, to make sure that the 
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synthetic lethality can be repeated in at least one colony (Fig 5.1C). 
Table 5.1 Mutations of myo2 tail sensitized strains 
 
Bold: amino acids that cluster in the Rab binding site 
Name Mutations 
myo2-41 1462 I to T  
myo2-42  1416 N to D      
1571 Q to H  
myo2-43  1446 L to P  
myo2-44  1310 L to Q      
1475 I to S  
myo2-45  1242 N to T      
1448 V to A  
myo2-46  1446 L to P  
myo2-47  1347 F to S  
myo2-48  1295 K to E      
1369 M to K      
1453 I to N      
1478 Y to F  
myo2-49  1446 L to P      
1519 S to C  
myo2-50  1411 L to P      
1431 D to V  
myo2-51  1444 K to M  
myo2-52  1446 L to R  
myo2-53  1186 D to V     
1416 N to Y  
myo2-54  1346 I to T      
1491 I to T      
1541 K to N  
myo2-55  1347 F to Y  
myo2-56  1331 L to F      
1336 A to S  
myo2-57  1367 W to R      
1415 Y to S      
1520 S to G  
 
 
 
As you can see, some mutations have shown multiple times, like 1446 L 
to P, and they cluster mainly to the Rab binding sites (Fig 5.1A and B).  
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Figure 5.1 Mutations of myo2 tail sensitized strains. 
(A) For convenience of comparison, this figure was adopted from paper from 
Pashkova and Weisman in 2005 and 2006, showing the two subdomains of 
Myo2p tail and the important amino acids of the Rab binding site on the 
structure. 
(B) Mutations of myo2 tail sensitized strains were mapped onto the structure, with 
the ones on the Rab binding site shown in red. You can see clearly clustering 
of mutations in this region. Some mutations that map to subdomain-I were not 
shown, but could possibly be important as well. 
 (C)After myo2 tail sensitized strains were identified, genomic DNA from 
themwas isolated. Using the genomic DNA as template, I cloned the myo2 
locus into the pRS303 MYO2-tail backbone and re-transformed them into 
smy1∆ + pRS316 SMY1 strain (BY MATa). 3 single colonies of different sizes 
were picked from each transformation and spotted onto –His and 
–His+5-FOA plates to test the synthetic lethality. You can see at least one 
colony can grow on –His but not on –His+5-FOA plates. 
 
Therefore, I tested the interaction of the mutant myo2-cctails with 
Smy1p and Sec4p respectively through Y2H. In this experiment, I cloned 
the mutant myo2 cctails into the pGADT7 Myo2-cctail backbone to 
generate the pGADT7 myo2 mutant-cctail series plasmids, which 
expresses AD-myo2-cctail protein in the nucleus. pAS2 Smy1, pBridge 
Sec4ΔC, pBridge Sec4ΔC +NLS-Smy1 plasmids were used to express the 
BD-Smy1p, BD- Sec4ΔC and BD- Sec4ΔC plus NLS-Smy1. The yeast 
two-hybrid experiment was done following the protocol described 
previously (Material and Method, Chapter 2). The results clearly tell us 
that most of the mutants have lost their interaction with Sec4p, while at 
the same time maintaining their interaction with Smy1p (Table 5.2). 
Unfortunately, expressing NLS-Smy1p from the pBridge 
Sec4ΔC+NLS-Smy1 plasmid (Made by Daniel Schott, the second multiple 
cloning site of pBridge carries a NLS-Smy1 construct) could not restore 
 61 
 
the interaction between Sec4p and the mutant Myo2p cctails, although 
the expression was not verified due to lack of Smy1p antibody. 
 
Table 5.2 Summary of Y2H interaction of myo2 tail mutants 
 
These results are base on a 5X dilution assay. ++: grow very well in all dilutions; 
+/-: grow weakly but can still be seen in the first 3 dilutions; -: no growth  
2DO: -Leu-Trp  3DO:-Leu-Trp-His  4DO:-Leu-Trp-His-Ade (very stringent) 
 
AD- 
cctail 
BD 2DO 
26 
3DO  
26 
4DO 
26 
2DO 
35 
3DO 
35 
 
WT 
Sec4p ++ ++ - ++ ++ 
Sec4P+NLS-Smy1p ++ ++ - ++ ++ 
Smy1p ++ ++ ++ + ++ 
 
Vec 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ - - ++ - 
 
myo2-12 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ ++ ++ ++ ++ 
 
myo2-14 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ - - ++ - 
 
myo2-16 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ ++ - ++ +/- 
 
myo2-41 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ ++ ++ ++ ++ 
 
myo2-42 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ ++ ++ ++ ++ 
 
myo2-43 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ ++ ++ ++ ++ 
 
myo2-44 
Sec4p ++ +/- - ++ - 
Sec4P+NLS-Smy1p ++ +/- - ++ - 
Smy1p ++ ++ ++ ++ ++ 
 Sec4p ++ +/- - ++ - 
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myo2-45 Sec4P+NLS-Smy1p ++ +/- - ++ - 
Smy1p ++ ++ - + - 
 
myo2-46 
Sec4p ++ +/- - ++ - 
Sec4P+NLS-Smy1p ++ +/- - ++ - 
Smy1p ++ ++ ++ ++ ++ 
 
myo2-47 
Sec4p ++ ++ - ++ ++ 
Sec4P+NLS-Smy1p ++ ++ - ++ ++ 
Smy1p ++ ++ ++ + ++ 
 
myo2-48 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ - - ++ - 
 
myo2-49 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ ++ ++ ++ ++ 
 
myo2-50 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ ++ ++ ++ ++ 
 
myo2-51 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ ++ ++ + ++ 
 
myo2-52 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ ++ ++ ++ ++ 
 
myo2-53 
Sec4p ++ - - ++ - 
Sec4P+NLS-Smy1p ++ - - ++ - 
Smy1p ++ ++ ++ ++ - 
 
myo2-54 
Sec4p ++ + - ++ ++ 
Sec4P+NLS-Smy1p ++ + - ++ ++ 
Smy1p ++ ++ ++ ++ +/- 
 
myo2-55 
Sec4p ++ ++ - ++ ++ 
Sec4P+NLS-Smy1p ++ ++ - ++ ++ 
Smy1p ++ ++ ++ ++ + 
 
myo2-56 
Sec4p ++ ++ - ++ ++ 
Sec4P+NLS-Smy1p ++ ++ - ++ ++ 
Smy1p ++ ++ ++ ++ ++ 
 
myo2-57 
Sec4p ++ +/- - ++ - 
Sec4P+NLS-Smy1p ++ +/- - ++ - 
Smy1p ++ ++ ++ + - 
5.2 Screen of smy1 mutants 
To screen for smy1 mutants in the sensitized strains, a smy1 mutant 
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library was constructed using error-prone PCR. This library was based on 
pRS304 vector and the whole SMY1 gene was mutagenized. After 
linearization with BamHI and transformation into the cell, this 
mutagenized smy1 will replace the endogenous allele through 
homologous recombination, and will be linked to a TRP1 gene.  
I started my screen in myo2 head mutant myo2-247, which grows at a 
slightly slower rate than WT and is not temperature sensitive. The other 
head mutant myo2-209 has a strong growth defect by itself and 
therefore was not chosen here, because it would be hard to interpret the 
phenotype of the double mutants if the contribution from smy1 cannot 
be determined. Transforming pRS304 smy1 into myo2-247 gave me 
roughly 5,000 colonies. From them I picked 1,500 colonies and tested the 
growth at 26 and 37. Only two mutants were found to be TS, which 
are myo2-247 smy1-15 and myo2-247 smy1-17. After that, genomic DNA 
was extracted and insertion was verified through a PCR reaction (Fig 
5.2A). Then, both alleles were sequenced: smy1-15 has a single point 
mutation in Smy1p head (269F to L); smy1-17 has two point mutations in 
the head domain as well (117F to S and 121S to F). The latter is 
interesting because this region was homologous to other Kinesin’s 
ATPase region (Lillie and Brown, 1992). At last, both of the mutations 
were transformed back to myo2-247 cells to make sure that the TS 
phenotype was because of the synthetic effect of the two mutations. 
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Unfortunately, myo2-247 smy1-15 didn’t show the same heat sensitivity 
as before and was therefore abandoned.  
 
Fig 5.2 (A) smy1 insertion verification. One primer corresponds to the sequence 
before the 5’ homologous region of SMY1, the other overlaps with sequence in 
the AMP gene. Product will only be seen when smy1 is correctly inserted. 
 
In addition, a screen in myo2 tail sensitized strains was also performed. I 
picked 5 different sensitized strains, myo2-41, myo2-43, myo2-47, 
myo2-51 and myo2-57 because they all carry mutations near the Rab 
binding site. Similarly to the previous screen, I picked ~2,000 colonies 
from every background and screened for temperature-sensitive growth 
at 37. After careful selection and verification, 33 mutants were 
identified (Fig 5.2B). Through the same PCR reaction as in Figure 5.2A, 
they were all confirmed to have smy1 insertion at the right locus. 
Sequencing of these mutants is still in progress, with part of the results 
shown in Table 5.3.  
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Figure 5.2 (B) smy1 mutants TS test. I got 16 mutants in myo2-41 background, 
4 mutants in myo2-47 background, 1 mutant in myo2-51 background and 6 
mutants in myo2-57 background. Unfortunately I didn’t get any mutants in 
myo2-43 background, although over 2,000 colonies were picked. Note that 
another myo2-247 smy1 mutant is also put here, just for convenience. After I 
sequenced the smy1 locus, I named these smy1 alleles. Two of the mutants didn’t 
have any mutation so I put a “?” as the allele name. 
 
 
Table 5.3 smy1 mutants sequencing result 
Thanks to Kyaw Myo Lwin for his contribution in this experiment. There are two 
mutants with no mutations in the SMY1 locus, so I didn’t assign allele number to 
them and left a “?” there. 
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myo2  
sensitized strain 
smy1 allele smy1 nt  change smy1 AA change 
 
 
 
 
 
 
 
myo2-57 
 
smy1-2 
76 TàC 
176 GàA 
1217 T à C 
26 CàR 
59 RàH 
406 I à T 
 
smy1-4 
1062 A à G 
1161 C à T 
1498 T à C 
1761 C à T 
354 T à T (silent) 
387 D à D (silent) 
500 S à P 
587 I à I (silent) 
smy1-5 650 T à C 
713 T à C 
217 V à A  
238 V à A 
smy1-6 800 A à G 267 E à G 
smy1-7 839 A à G 
1151 T à C 
280 D à G 
384 F à S 
smy1-1 190 TàC 
434 TàC 
64 LàL (silent) 
145 LàP 
 
 
 
myo2-47 
smy1-1 190 TàC 
434 TàC 
64 LàL (silent) 
145 LàP 
smy1-8 170 TàC 
993 TàG 
57 LàP 
331 LàL (silent) 
smy1-9 508 AàC 
929 C à T 
170 TàP 
310 A à V 
? N/A - 
myo2-51 smy1-10 170 TàC 57 LàP 
myo2-247 ? N/A - 
 
 
 
 
 
 
 
 
 
myo2-41 
 
 
 
 
 
 
 
 
smy1-11 1588 A à G 529 N à D 
smy1-12 293 TàG 98 IàR 
smy1-13 515 AàG 172 DàG 
smy1-14 866 T à G 289 I à S 
smy1-3 805 T à C 269 F à L 
smy1-15 337 TàC 113 YàH 
 
smy1-2 
76 TàC 
176 GàA 
1217 T à C 
26 CàR 
59 RàH 
406 I à T 
smy1-16 501 GàA 
1087 A à G 
167 MàI 
363 R à R (silent) 
smy1-10 170 TàC 57 LàP 
smy1-18 875 T à G 292 L à W 
smy1-19 381 AàG 
404 CàT 
127 SàS (silent) 
135 PàL 
smy1-20 85 GàA 
352 AàG 
29 EàK 
118 SàG 
smy1-3 805 T à C 269 F à L 
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myo2-41 
smy1-21 892 T à C 298 S à P 
smy1-22 700 A à G 234 R à G 
smy1-1 190 TàC 
434 TàC 
64 LàL (silent) 
145 L àP 
 
 
 
Figure 5.2 (C) Mapping mutations of smy1 mutants to SMY1 gene. Only 
non-silent mutations are shown here. smy1-8 and smy1-10 encode the same 
protein, but smy1-8 has one silent mutation. You can see clearly the clustering of 
mutations in the head domain. 
 
5.3 Characterizing the phenotype of myo2-247 smy1-17 
Most of the smy1 mutants were identified recently. Therefore, I have not 
been able to characterize their phenotype. The mutant myo2-247 
smy1-17 was identified earlier, so the results will be shown here. 
First, I wanted to ask whether this smy1-17 allele is recessive or 
dominant. Therefore, I transformed WT MYO2 and SMY1 allele into the 
strain. Surprisingly, none of them can fully suppress the growth defect of 
the myo2-247 smy1-17 double mutant, even with overexpressed Smy1p. 
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Nevertheless, the temperature sensitivity is suppressed, indicating that 
at least this allele is not fully dominant (Fig 5.3A).  
 
Figure 5.3 (A) suppression test of myo2-247 smy1-17. In either myo2-247 or 
myo2-247 smy1-17 cells, a vector carrying MYO2, SMY1, SEC4, multiple copy of 
SMY1 or empty vector were transformed. Temperature sensitivity of this double 
mutant was indeed suppressed, but the strain always grew slowly. 
 
After that, I used GFP-Sec4p as a vesicle marker to study polarized 
secretion. At RT, myo2-247 smy1-17 showed a moderate phenotype 
compared to myo2-247 itself. GFP-Sec4p in myo2-247 smy1-17 cells 
occasional accumulated in the mother cell, while staying polarized in 
most cases. After a 2h shift to the restrictive temperature (37), I found 
a very dramatic change in the polarization of GFP-Sec4p in the double 
mutant, which became diffuse or formed bright puncta in the mother 
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cell. In summary, a secretion block was seen at restrictive temperature 
while actin cables were still intact (Fig 5.3B and C). Therefore, either 
Myo2p was detached from the vesicles or it had lost the ability to move 
its cargo while remaining binding to it. To clarify this, we need to 
investigate Myo2p localization. Therefore, I tried to conduct an 
immuno-fluorescence experiment using anti-Myo2 tail antibody in this 
mutant, but never succeeded. The reason was quite unexpected, that is, 
almost all Myo2p protein was degraded at 37 in myo2-247 smy1-17 
(Fig 5.3D). Since this smy1-17 allele actually destabilizes the Myo2p 
protein, I feel it may not be a good mutant to work with.  
Conclusion and Discussion 
This chapter is the most interesting and promising part of my research, 
which is to study the synthetic effect of smy1 mutants combined with 
other mutants. Smy1p was long known to be synthetic lethal with myo2 
head and tail mutants when deleted. What’s more, overexpression of 
Smy1p could suppress both head and tail myo2 mutants. With the fact 
that they also interact with each other and travel together, Smy1p is very 
likely to play some important role in Myo2p’s function. The hypothesis I 
proposed was that Smy1p actually enhances the interaction between 
Myo2p and secretory vesicle adaptors. In this model, it is easy to explain 
why overexpression of Smy1p would suppress myo2 tail mutants, 
because Smy1p brings Myo2p back to secretory vesicles. However, why  
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Figure 5.3 characterizing phenotype of double mutant 
(B) GFP-Sec4p staining in myo2-247 and myo2-247 smy1-17 cells. Cells were 
imaged after formaldehyde fixation. myo2-247 smy1-17 showed depolarized 
Sec4p staining. Actin cables were still fine, while Actin patches were located 
in the mother cell more frequently.  
(C) Quantification of phenotype. Blue is polarized GFP-Sec4p, green represents 
accumulated GFP-Sec4p, and teal is diffuse. This was based on three 
independent experiment 
(D) Myo2p is degraded in double mutant by anti-myo2 tail WB. myo2-247 was 
not very stable at high temperature by itself, and when became even more 
unstable when combined to smy1-17. 
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Smy1p could also suppress myo2 head mutants, of which myo2-66 was 
the only one known, is quite curious. One hint from previous research is 
that Daniel Schott once showed that myo2-66 is easily degraded at high 
temperature while overexpressing Smy1p rescues it (unpublished data). 
If we keep that in mind and look at the result I got for myo2-247, which is 
another myo2 head mutant, we find some similarity. myo2-247 is also 
unstable at high temperature and this effect is enhanced by a mutant 
smy1-17 allele. When the two mutants are combined, the cell grows very 
slowly and shows a severe secretion block. I didn’t check other 
organelles, but they should also be affected. Also, it would be interesting 
to know where smy1-17 localizes when we get the Smy1p antibody. 
Another exciting finding from this research is that almost all the myo2 
tail mutants that are synthetic lethal with smy1 deletion have mutations 
in the Rab binding sites. To support that, most of them indeed lose 
interaction with Sec4p. That means, when Myo2p has a problem binding 
to Sec4p, Smy1p becomes essential. What does that tell us? One 
possibility is that Smy1p actually enhances the interaction between 
Myo2p and Sec4p, but this could not be verified by the Y2H experiment. 
Maybe in vitro reconstitution using purified proteins would provide us 
with more information, as I have purified plenty of Smy1p protein. A 
second explanation is that, Smy1p actually bridges the interaction of 
Myo2p to other adaptors on secretory vesicles, of which PI4P could be a 
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candidate. To answer that question, raising the level of PI4P to see if it 
can rescue the synthetic lethality of myo2-16 smy1Δ would be very 
interesting. 
The new smy1 mutants provide a rich resource to study its function. 
From the sequences we got, 30 out of 34 (88%) non-silent mutations are 
in the head domain of Smy1p. Although we expect to see more 
mutations in the head domain because the homologous recombination 
happens in the tail region, such clustering of mutations is still surprising. 
One would speculate that either the head domain is very important so 
any mutation will have a big influence, or the tail domain is too vital for 
its function to have any mutation. Maybe some in vitro experiment like 
ATPase activity assay on the head domain would be helpful for us to 
understand this. 
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS 
In this thesis, I mainly introduced the work I have finished in the past two 
years and some ongoing work right now. This chapter will be a short 
summary. 
I started my exploration of Smy1p function by studying its localization, 
because I have a lot of doubt on the Trybus group’s paper, which claims 
Smy1p to bind to secretory vesicles and acts as an electrostatic tether. 
Through my experiments, I showed that Myo2p binding is essential but 
not sufficient for Smy1p localization, which clearly disagrees with their 
model. What’s more important, this result indicates that a secretory 
vesicle and Myo2p synergy exists and Smy1p probably functions as part 
of a large adaptor complex. 
Following that, I constructed a series of Smy1p truncation constructs and 
tried to find a localization domain. Luckily or unluckily, I found that the 
localization of Smy1p is very complicated, influenced by all three 
domains in different ways. Together with the expression level data, I 
proposed that there is a balance between the head and the tail, while 
the coiled-coil region is a bridge or enhancer. This part is interesting but I 
think we are still far away from understanding the function of each 
domain when the function of the whole protein is unclear. 
In an attempt to understand Smy1’s function, I set out to create some 
synthetic mutants. One way to create such mutants in existing 
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conditional mutants is to physically get rid of Smy1p protein. I adopted a 
method which took advantage of the proteasome system and the 
controllable GAL promotor. Although the experiment didn’t work in the 
expected way, the result was still informative. Smy1p depletion in 
myo2-16 cells causes a massive secretion block, which supports our 
model that Smy1p functions in polarized secretion. Another ongoing 
project is to create smy1 myo2 double mutants. I spent a long time 
refining the whole system and to manually pick the colonies. Right now 
we have more than 30 mutants to work with. Studying their phenotype 
should be enlightening and exciting. 
As future directions, there are several questions I want to ask: 
(1) How is Smy1p involved in polarized secretion?  
All the evidence I got prompts me to propose the hypothesis that Smy1p 
is an accessory protein that bridges the interaction between Myo2p and 
a secretory vesicle. This bridging or enhancing effect is vital when Myo2p 
and Sec4p have problems binding to each other. However, how can we 
design experiment to support this idea? A Y2H experiment in which my 
myo2 tail mutants and Sec4p’s interaction were tested when NLS-Smy1p 
is expressed gave us a negative result, but the expression of NLS-Smy1p 
was not verified. With the Smy1p antibody available in the future, I 
strongly suggest to repeat that experiment. Besides, in vitro 
reconstitution has always been a promising and convincing approach. 
 75 
 
Myo2p binding to Sec4p has been confirmed by Felipe Santiago, but its 
binding to PI4P and Smy1p couldn’t be repeated. Further refinement of 
the system is needed (proportion and purity of proteins, buffer, PI4P 
level, etc.). In addition, physical depletion experiment in sec mutants 
would also be helpful for us to establish a model for Smy1p function. 
(2) At which step does Smy1p join in vesicle transport and when does it 
leave?  
The primary problem we need to figure out is whether Smy1p localizes 
to a special type of vesicle? Is Smy1p sorted or participate in sorting? To 
answer these questions, we have to double label Smy1p and Sec4p and 
study their movement carefully. Right now Smy1p-3mcherry is too dim 
to give a clear signal on secretory vesicles, while Smy1p-3GFP works 
fairly well. So a red Sec4p is definitely needed.  
Besides that, we can conduct FRAP experiment to study Smy1p’s life 
cycle. In this way, we will be able to compare its behavior to Sec4p and 
Myo2p and further understand its interaction. Once this is done, its life 
cycle in myo2 and other mutants can be determined. Also, the mutant 
smy1p would also be interesting subjects. 
(3) What exactly does Smy1p overexpression do to the cell?  
Myo2p hyperpolarization was observed when Smy1p is overexpressed in 
WT cells. Two explanations are possible. One is that each vesicle carries 
more Myo2p, and the Myo2p life cycle stays the same. The other one is 
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that Myo2p stays in the bud for a longer time. Right now with Kirk 
Donovan’s preliminary data, the second hypothesis seems to be favored. 
To further confirm this, we need to do FRAP experiment on Myo2p-3GFP 
when Smy1p is overexpressed or not. Comparing the two groups would 
solve this problem. 
If Myo2p does stay longer in the bud when Smy1p is overexpressed, we 
want to know why that would happen. Is Sec4p locked in its GTP form for 
longer? Or is Myo2p binding to Sec4p enhanced so much that even 
GDP-bound Sec4p could still bind to Myo2p? There would be a lot of 
experiments to work on. 
(4) What are the binding partners of Smy1p? Does Smy1p bind PI4P? 
Right now Myo2p is the only interacting protein that we know, but this 
interaction cannot be detected using in vitro pull-down assay, 
presumably because the interaction is transient or weak. Besides, Smy1p 
may bind to PI4P although its overexpression doesn’t suppress pik1-83. 
However, this could be due to a complication caused by lower PI4P levels. 
Further in vitro reconstitution may be a good system to solve these 
problems. At last, what else does Smy1p bind? In vitro pull-down 
experiments are proposed for a long time but I didn’t have the chance to 
try. 
(5) What are the functions of each domain of Smy1p? Why is the 
N-terminal cleaved? Why do truncations have different expression 
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levels?  
To investigate these problems, I believe we have to start from analyzing 
the mutants I identified. 88% of the mutants have mutations in the head 
domain, indicating the importance of it. I would suggest purifying the 
head domain and testing the ATPase activity. Besides, does it bind to 
Myo2p also? If so, an interesting model would be generated. N-terminal 
modification of this domain is also an intriguing question to investigate. 
In total, after characterizing the phenotype of the mutants, we can 
extend our research to the molecular level and finally solve the mystery 
of Smy1p. 
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APPENDIX: STRIN LIST 
ABY# Description Genotype Source 
1655 WT MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 Felipe 
Santiago-Tira
do 
2702 myo2-12 MATa myo2-12::HIS3 his3Δ1 ura3Δ0 
leu2Δ0 met15Δ0 
Felipe 
Santiago-Tira
do 
2704 myo2-14 MATa myo2-14::HIS3 his3Δ1 ura3Δ0 
leu2Δ0 met15Δ0 
Felipe 
Santiago-Tira
do 
2705 myo2-16 MATa myo2-16::HIS3 his3Δ1 ura3Δ0 
leu2Δ0 met15Δ0 
Felipe 
Santiago-Tira
do 
? myo2-24 MATa myo2-24::HIS3 his3Δ1 ura3Δ0 
leu2Δ0 met15Δ0 
Irina 
Chernyakov 
511 sec2-56 MATx sec2-56 ura3-52 leu2-3,112 Felipe 
Santiago-Tira
do 
? sec4-8 MAT? sec4-8 ura3-52 leu2-3,112 Felipe 
Santiago-Tira
do 
? Y8830 ? Haiyuan Yu 
? Y8910 ? Haiyuan Yu 
3304 WT Smy1-3HA MATa Smy1-3HA::KanR his3Δ1 ura3Δ0 
leu2Δ0 met15Δ0 
this study 
3305 myo2-14 
Smy1-3HA 
MATa myo2-14::HIS3 Smy1-3HA::KanR 
his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
this study 
3306 myo2-16 
Smy1-3HA 
MATa myo2-16::HIS3 Smy1-3HA::KanR 
his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
this study 
3307 myo2-247 trp1Δ MATa myo2-247::HIS3 trp1Δ::KanR his3Δ1 
ura3Δ0 leu2Δ0 met15Δ0 
this study 
3308 myo2-247 
smy1-17 
MATa myo2-247::HIS3 trp1Δ::KanR 
smy1-17:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3309 myo2-16 bni1Δ MATa myo2-16::HIS3 bni1Δ::KanR his3Δ1 
ura3Δ0 leu2Δ0 met15Δ0 
this study 
3310 myo2-16 bnr1Δ MATa myo2-16::HIS3 bnr1Δ::KanR his3Δ1 
ura3Δ0 leu2Δ0 met15Δ0 
this study 
3311 trp1Δ MATx trp1Δ::KanR his3Δ1 ura3Δ0 leu2Δ0 
lys2Δ0 
this study 
3312 smy1-17 MATx trp1Δ::KanR smy1-17:: TRP1 his3Δ1 this study 
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ura3Δ0 leu2Δ0 lys2Δ0 
3313 trp1Δ MATa trp1Δ::KanR his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3314 myo2-16 smy1Δ 
415 UBI-R-Smy1 
MATa myo2-16::HIS3 smy1Δ::KanR his3Δ1 
ura3Δ0 leu2Δ0 met15Δ0 pRS415 
UBI-R-Smy1-6his 
this study 
3315 trp1Δ myo2-47 MATa myo2-47::HIS3 trp1Δ::KanR his3Δ1 
ura3Δ0 leu2Δ0 met15Δ0 
this study 
3316 trp1Δ myo2-57 MATa myo2-57::HIS3 trp1Δ::KanR his3Δ1 
ura3Δ0 leu2Δ0 met15Δ0 
this study 
3317 trp1Δ myo2-51 MATa myo2-51::HIS3 trp1Δ::KanR his3Δ1 
ura3Δ0 leu2Δ0 met15Δ0 
this study 
3318 trp1Δ myo2-43 MATa myo2-43::HIS3 trp1Δ::KanR his3Δ1 
ura3Δ0 leu2Δ0 met15Δ0 
this study 
3319 trp1Δ myo2-41 MATa myo2-41::HIS3 trp1Δ::KanR his3Δ1 
ura3Δ0 leu2Δ0 met15Δ0 
this study 
3320 myo2-41 
smy1-15 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-15:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3321 myo2-41  
smy1-2 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-2:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3322 myo2-41 
smy1-16 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-16:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3323 myo2-47  
smy1-1 
MATa myo2-47::HIS3 trp1Δ::KanR 
smy1-1:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3324 myo2-47 
smy1-8 
MATa myo2-47::HIS3 trp1Δ::KanR 
smy1-8:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3325 myo2-47  
smy1-9 
MATa myo2-47::HIS3 trp1Δ::KanR 
smy1-9:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3326 myo2-47  
smy1-? 
MATa myo2-47::HIS3 trp1Δ::KanR 
smy1-?:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3327 myo2-57  
smy1-2 
MATa myo2-57::HIS3 trp1Δ::KanR 
smy1-2:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3328 myo2-57  
smy1-4 
MATa myo2-57::HIS3 trp1Δ::KanR 
smy1-4:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3329 myo2-57  MATa myo2-57::HIS3 trp1Δ::KanR this study 
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smy1-5 smy1-5:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
3330 myo2-57  
smy1-6 
MATa myo2-57::HIS3 trp1Δ::KanR 
smy1-6:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3331 myo2-41  
smy1-3 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-3:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3332 myo2-41 
smy1-21 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-21:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3333 myo2-41 
smy1-22 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-22:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3334 myo2-41  
smy1-1 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-1:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3335 myo2-41 
smy1-11 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-11:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3336 myo2-41 
smy1-12 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-12:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3337 myo2-41 
smy1-13 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-13:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3338 myo2-41 
smy1-14 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-14:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3339 myo2-57  
smy1-7 
MATa myo2-57::HIS3 trp1Δ::KanR 
smy1-7:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3340 myo2-57  
smy1-1 
MATa myo2-57::HIS3 trp1Δ::KanR 
smy1-1:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3341 myo2-57 
smy1-10 
MATa myo2-57::HIS3 trp1Δ::KanR 
smy1-10:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3342 myo2-41 
smy1-20 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-20:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3343 myo2-41 
smy1-10 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-10:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
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3344 myo2-41 
smy1-18 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-18:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3345 myo2-41 
smy1-19 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-19:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3346 myo2-247 
smy1-? 
MATa myo2-247::HIS3 trp1Δ::KanR 
smy1-?:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
3347 myo2-41  
smy1-3 
MATa myo2-41::HIS3 trp1Δ::KanR 
smy1-3:: TRP1 his3Δ1 ura3Δ0 leu2Δ0 
met15Δ0 
this study 
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